Company
Gan & Lee Pharmaceuticals Co. Ltd
Headquarters: Beijing, China
Employees: 2,934
Market Cap
CN¥33.89 Billion
CNY as of July 1, 2025
US$4.73 Billion
Gan & Lee Pharmaceuticals Co. Ltd Categories
China Healthcare Medical Instruments & SuppliesChina Healthcare China Medical Instruments & Supplies
Top Competitors by Market Capitalization
Industry: Medical Instruments & Supplies
| Company | Market Cap (USD) |
|---|---|
| Intuitive | $193.76 B |
| EssilorLuxottica SA | $128.90 B |
| Becton, Dickinson and Company | $50.81 B |
| Alcon Inc. | $44.33 B |
| HOYA Corp | $40.30 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and commercialization insulin and its analogues primarily in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro; Raplin, an insulin aspart injection; and Raplin 30, an insulin aspart 30 injection, as well as medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.
Financials
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | CN¥3.47 B |
| EBITDA | CN¥727.0 M |
| Gross Profit TTM | CN¥2.62 B |
| Profit Margin | 23.94% |
| Operating Margin | 22.69% |
| Quarterly Revenue Growth | 75.80% |
Stocks & Indices
Gan & Lee Pharmaceuticals Co. Ltd has the following listings and related stock indices.
Stock: SSE: 603087 wb_incandescent